Cetrimonium Bromide (CTAB)
(Synonyms: 西曲溴铵; CTAB; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide) 目录号 : GC15892
一键复制产品信息
Cetrimonium Bromide (CTAB)是一种常用的表面活性剂，具有内在的抗菌特性，能够作为药物的增溶剂。
Cas No.:57-09-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cetrimonium Bromide (CTAB), a common used surfactant, act as a drug solubilizer with intrinsic antibacterial properties [1]. Cetrimonium Bromide can reduce the germination rate of Brassica campestris, affect the root elongation after seed germination, decrease the chlorophyll content in plant leaves, and increase the antioxidant enzyme activity of plants[2]. Cetrimonium Bromide has been widely used for the rapid extraction of nucleic acids from plant tissues [3].
In vitro, Cetrimonium Bromide treatment for 48 hours significantly inhibited the viability of HOS, MG63 and U2OS cells, with IC50 values of 4.949, 3.500 and 4.212µM respectively[4]. 5.0μM Cetrimonium Bromide treatment for 16 hours significantly reduced the adhesion of SCC4 cells and altered cell morphology[5]. Treatment with 10µM Cetrimonium Bromide for 48 hours resulted in an increase in the number of apoptotic cells in NDRG1-deficient DU-145 cells, accompanied by an increase in cleaved PARP levels[6].
In vivo, Cetrimonium Bromide treatment (5mg/kg/day; i.p.) for 5 consecutive days can reduce the tumor-forming ability of FaDu cell-bearing mice and slow down tumor growth[7]. Cetrimonium Bromide (13.7mmol/kg) was injected via tail vein once every three days for 30 days, which significantly reduced the metastasis of breast cancer from the 4T1 orthotopic breast cancer model in mice to the lungs[8].
References:
[1] Carvalho G C, Marena G D, Karnopp J C F, et al. Cetyltrimethylammonium bromide in the synthesis of mesoporous silica nanoparticles: General aspects and in vitro toxicity[J]. Advances in Colloid and Interface Science, 2022, 307: 102746.
[2] Song U, Kim H E. Assessing the phytotoxicity of cetrimonium bromide in plants using eco-physiological parameters[J]. Journal of Ecology and Environment, 2016, 40(1): 14.
[3] Allen G C, Flores-Vergara M A, Krasynanski S, et al. A modified protocol for rapid DNA isolation from plant tissues using cetyltrimethylammonium bromide[J]. Nature protocols, 2006, 1(5): 2320-2325.
[4] Da W, Tao L, Zhu Y. The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway[J]. International Journal of Oncology, 2021, 59(1): 42.
[5] Yue C H, Chen C H, Pan Y R, et al. Cetyltrimethylammonium bromide disrupts mesenchymal characteristics of human tongue squamous cell carcinoma SCC4 cells through modulating canonical TGF-β/Smad/miR-181b/TIMP3 signaling pathway[J]. Anticancer Research, 2021, 41(12): 6095-6104.
[6] Wissing M D, Mendonca J, Kim E, et al. Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells[J]. Cancer Biology & Therapy, 2013, 14(5): 401-410.
[7] Ito E, Yip K W, Katz D, et al. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer[J]. Molecular pharmacology, 2009, 76(5): 969-983.
[8] Li N, Chen Y, Yang Y, et al. Cetyltrimethylammonium bromide inhibits the metastasis of breast cancer to the lungs by inhibiting epithelial–mesenchymal transition[J]. Biocell, 2022, 46(6): 1473.
Cetrimonium Bromide (CTAB)是一种常用的表面活性剂，具有内在的抗菌特性，能够作为药物的增溶剂 [1]。Cetrimonium Bromide能降低Brassica campestris种子的萌发率，影响种子萌发后的根伸长，减少植物叶片中的叶绿素含量，并提高植物的抗氧化酶活性[2]。Cetrimonium Bromide已广泛用于从植物组织中快速提取核酸[3]。
在体外，Cetrimonium Bromide处理48小时显著抑制了HOS、MG63和U2OS细胞的活力，IC50值分别为4.949、3.500和4.212µM[4]。5.0µM的Cetrimonium Bromide处理16小时显著降低了SCC4细胞的粘附能力并改变了细胞形态[5]。10µM的Cetrimonium Bromide处理48小时导致NDRG1缺陷型DU-145细胞凋亡数量增加，并伴有裂解PARP水平的升高
在体内，连续5天腹腔注射Cetrimonium Bromide（5mg/kg/day）能够降低FaDu细胞-荷瘤小鼠的成瘤能力并减缓肿瘤生长[7]。每隔三天通过尾静脉注射Cetrimonium Bromide（13.7mmol/kg），持续30天，显著减少了4T1小鼠原位乳腺癌模型中的乳腺癌向肺部的转移[8]。
| Cell experiment [1]: | |
Cell lines | NDRG1-deficient DU-145 cells |
Preparation Method | The NDRG1-deficient DU-145 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified incubator at 37°C and 5% CO2. The cells were seeded onto culture plates (1.5×103 cells per well), cultured overnight, and then treated with different concentrations of Cetrimonium Bromide (0.5, 1, 4, 10, 20, and 50µM) for 48 hours. After adding the MTS reagent and incubating for 2-3 hours, the absorbance at 490nm was measured. |
Reaction Conditions | 0.5, 1, 4, 10, 20, and 50µM; 48h |
Applications | Cetrimonium Bromide treatment reduced cell viability of NDRG1-deficient DU-145 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male nude mice |
Preparation Method | HOS cells (2×106) suspended in 100µl PBS were subcutaneously inoculated into the backs of 4-week-old male nude mice. Three days after inoculation, the mice were randomly divided into 3 groups (n=4). Subsequently, each group of mice was intraperitoneally injected with Cetrimonium Bromide (20mg/kg) once every 3 days for a total of 20 days. The control group was injected with the same volume of normal saline. During the treatment period, the body weight and tumor size of the mice were monitored every 3 days. After 20 days of Cetrimonium Bromide treatment, the mice were euthanized by cervical dislocation, and the tumors and major organs (including liver, lung, kidney, spleen, and heart) of each group of mice were collected and immersed in 4% formalin solution for immunohistochemical staining and hematoxylin-eosin (H&E) staining. The formula for calculating tumor volume is: Volume=1/2 (length×width2). |
Dosage form | 20mg/kg; every 3 days for 20 days; i.p. |
Applications | Cetrimonium Bromide treatment resulted in a significant reduction in tumor volume and weight in mice without organ toxicity. |
References: | |
| Cas No. | 57-09-0 | SDF | |
| 别名 | 西曲溴铵; CTAB; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide | ||
| 化学名 | hexadecyl(trimethyl)azanium;bromide | ||
| Canonical SMILES | CCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-] | ||
| 分子式 | C19H42N.Br | 分子量 | 364.45 |
| 溶解度 | ≥ 5.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7439 mL | 13.7193 mL | 27.4386 mL |
| 5 mM | 548.8 μL | 2.7439 mL | 5.4877 mL |
| 10 mM | 274.4 μL | 1.3719 mL | 2.7439 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet